Journal of Eye & Cataract Surgery Open Access

  • ISSN: 2471-8300
  • Journal h-index: 5
  • Journal CiteScore: 0.38
  • Journal Impact Factor: 0.29
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Non-coding RNAs- novel therapeutic targets for diabetic retinopathy

Joint Event on 3rd Edition of International Conference on Eye and Vision & 2nd International Conference and Expo on Advanced Eye Care and Cataract
June 14-15, 2018 Rome, Italy

Subrata Chakrabarti

Western University, London

Posters & Accepted Abstracts: J Eye Cataract Surg


In the post genomic era, we have now the capacity to develop novel therapies, targeting epigenetic mechanisms. Such targets in the context of diabetic retinopathy include histone acetylation, histone methylation, microRNAs and long non-coding RNAs. We focused on microRNAs and long non-coding RNAs as potential treatment targets of diabetic retinopathy. In diabetic retinopathy, glucose-induced damage leads to changes in the cellular transcription. Endothelial cells (ECs), being exposed to hyperglycemia changes their synthetic and secretory phenotype. Subsequently, other cell in the retina is affected. We have demonstrated that diabetes activates transcription factors (eg: NFκB, regulated by transcription co-activators, p300). We have also demonstrated that some long noncoding RNAs (lncRNAs) such as ANRIL and MALAT1 as well as microRNAs (eg. mir2146a, miR200b) regulate glucose induced increased production of angiogenic factors, extracellular matrix (ECM) proteins and inflammatory cytokines. Our laboratory has carried out large number of experiments in the ECs, in animals with type 1 and type 2 diabetes and in the retina and vitreous from diabetic patients. Data generated from these studies shows novel pathogenetic mechanisms and drug development targets for diabetic retinopathy.